All In Biotech

Drug Trial Radar · NCT06915766

Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

Intermediate-Size Patient Population Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Cogent Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Apr 8, 2025

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

The purpose of this expanded access program (EAP) protocol is to provide investigational bezuclastinib to patients with a diagnosis of nonadvanced systemic mastocytosis (NonAdvSM) or advanced systemic mastocytosis (AdvSM) who have received and failed or been intolerant to at least one standard approved therapy and/or have no comparable or satisfactory alternative therapy options.

Conditions

  • Systemic Mastocytoses, Indolent
  • Systemic Mastocytoses, Aggressive

Interventions

  • BezuclastinibDrug

    Drug: Bezuclastinib Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Orso Health/Modena Asthma Allergy

    La Jolla, California · Available

  • Scripps Green Hospital

    La Jolla, California · Available

  • UCLA Ronald Reagan Medical Center

    Los Angeles, California · Available

  • Sneeze Wheeze & Itch Associates LLC Clinical Research Center

    Normal, Illinois · Available

  • Indiana University Health

    Indianapolis, Indiana · Available

  • Northern Light Eastern Maine Medical Center

    Bangor, Maine · Available

  • Walter Reed

    Bethesda, Maryland · Available

  • AllerVie Health

    Glenn Dale, Maryland · Available

  • Boston Specialists

    Boston, Massachusetts · Available

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Available

  • Michigan Medicine- University of Michigan

    Ann Arbor, Michigan · Available

  • Mayo Clinic

    Rochester, Minnesota · Available

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri · Available

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire · Available

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Available

  • Duke Blood Cancer Center

    Durham, North Carolina · Available

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio · Available

  • AIR Care

    Dallas, Texas · Available

  • Texas Children's Hospital

    Houston, Texas · Available

  • The University of Texas, MD Anderson Cancer Center

    Houston, Texas · Available

  • University of Utah - Huntsman Cancer Institute

    Salt Lake City, Utah · Available

  • Allergy Associates of Utah

    Sandy City, Utah · Available

  • Northwest Medical Specialties

    Tacoma, Washington · Available

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.